Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
Completed · Phase 2 · Has a placebo group
Conditions studied: Lupus Nephritis
In brief
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).
Key facts
- Study ID
- NCT02547922
- Run by
- AstraZeneca
- People needed
- 147
- Starts
- 2015-11-04
- Expected to finish
- 2021-01-18
- Last updated by the study team
- 2021-11-24
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Phoenix, Arizona, United States
- Research Site — La Jolla, California, United States
- Research Site — Los Angeles, California, United States
- Research Site — Thousand Oaks, California, United States
- Research Site — Aurora, Colorado, United States
- Research Site — DeBary, Florida, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Newark, New Jersey, United States
- Research Site — Great Neck, New York, United States
- Research Site — New Hyde Park, New York, United States
- Research Site — New York, New York, United States
- Research Site — New York, New York, United States
- Research Site — The Bronx, New York, United States
- Research Site — Columbus, Ohio, United States
- Research Site — Oklahoma City, Oklahoma, United States
- Research Site — Memphis, Tennessee, United States
- Research Site — Buenos Aires, Argentina
- Research Site — Córdoba, Argentina
- Research Site — Rosario, Argentina
- Research Site — Adelaide, Australia
- Research Site — Clayton, Australia
- Research Site — Parkville, Australia
- Research Site — Westmead, Australia
- Research Site — Brussels, Belgium
- Research Site — Glendale, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.